Ultragenyx Pharmaceutical Inc.

Form 3

January 30, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Sharp Shalini

(Last)

(First) (Middle)

Statement

(Month/Day/Year)

01/30/2014

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Ultragenyx Pharmaceutical Inc. [RARE]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

See Remarks

5. If Amendment, Date Original

Filed(Month/Day/Year)

C/O ULTRAGENYX **PHARMACEUTICAL**

INC., Â 60 LEVERONI COURT

(Street)

Director _X__ Officer (give title below) (specify below)

10% Owner Other

6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

NOVATO. CAÂ 94949

(City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security

(Instr. 4)

2. Amount of Securities Beneficially Owned

(Instr. 4)

3. Ownership 4. Nature of Indirect Beneficial Ownership

Form: Direct (D) or Indirect (Instr. 5)

(I) (Instr. 5)

Common Stock 79,755

Â D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security

2. Date Exercisable and **Expiration Date**

3. Title and Amount of Securities Underlying **Derivative Security** (Instr. 4)

5. 4. Ownership Conversion or Exercise Form of

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Price of Derivative Derivative Security:

Edgar Filing: Ultragenyx Pharmaceutical Inc. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	(1)	08/01/2022	Common Stock	111,663	\$ 0.815	D	Â
Stock Option (Right to Buy)	(2)	10/31/2023	Common Stock	39,878	\$ 6.8646	D	Â

Reporting Owners

Reporting Owner Name / Address		Relationships				
	Director	10% Owner	Officer	Other		
Sharp Shalini C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO, CA 94949	Â	Â	See Remarks	Â		

Signatures

By: /s/ Shalini
Sharp

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 1/4th of the option shall vest one year from May 21, 2012 and then the remaining shares vest monthly until May 21, 2016, provided the Reporting Person has not terminated services with the Issuer.
- (2) 1/4th of the option shall vest one year from November 1, 2013 and then the remaining shares vest monthly until November 1, 2017, provided the Reporting Person has not terminated services with the Issuer.

Â

Remarks

Chief Financial Officer and Senior Vice President

Exhibit List

Exhibit 24 - Limited Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2